Article
Identifying optimal first-line immune checkpoint inhibitors based regiments for advanced non-small cell lung cancer without oncogenic driver mutations: A systematic review and network meta-analysis.
PloS one - 1 Jan 2023
Liu Tingting, Wu Sijia, Fang Weiwei, Li Hongkai, Su Lili, Qi Guiye, Li Huaichen, Liu Yao
Abstract excerpt
BACKGROUND: Immune checkpoint inhibitors (ICIs) have changed the treatment pattern of advanced and metastatic NSCLC. A series of ICI based therapies have emerged in the first-line treatment field, but the comparative efficacy was unclear. METHOD: We searched multiple databases and abstracts of major conference proceedings up to Apri1, 2022 for phase III randomised trials of advanced driver-gene wild type NSCLC...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.